1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy
    Meeting Abstract

    Nghiem, P.; Bhatia, S.; Brohl, A. S.; Hamid, O.; Mehnert, J. M.; Terheyden, P.; Shih, K. C.; Brownell, I.; Lebbé, C.; Lewis, K. D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission
    Meeting Abstract

    O'Cearbhaill, R. E.; Gnjatic, S.; Aghajanian, C.; Iasonos, A.; Konner, J. A.; Losada, N.; Sarasohn, D.; Rasalan, T.; Tew, W. P.; Zamarin, D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Apalutamide + abiraterone + leuprolide with stereotactic, ultra-hypofractionated radiation (AASUR) in very high risk prostate cancer (PCa)
    Meeting Abstract

    McBride, S. M.; Zelefsky, M. J.; Spratt, D. E.; Kollmeier, M.; Slovin, S. F.; Aghalar, J.; Hearn, J. W.; Den, R. B.; Deville, C.; Borofsky, K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Association of body mass index (BMI) with overall survival (OS) in metastatic melanoma (MM) patients (pts) treated with combined anti-CTLA4 + anti-PD1
    Meeting Abstract

    McQuade, J. L.; Warner, A. B.; Li, M. M.; Chon, J.; Haydu, L. E.; Daniel-MacDougall, C.; Hess, K. R.; Johnson, D. B.; Menzies, A. M.; Davies, M. A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Physicians' documented performance of shared decision-making with chronic lymphocytic leukemia patients
    Meeting Abstract

    Mato, A. R.; Davids, M. S.; Carter, J. D.; Greene, L.; Sapir, T.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Baseline demographics and disparities in cancer registration trials: An analysis of US Food and Drug Administration approved drugs in 2015 and 2016
    Meeting Abstract

    Maniar, R.; Green, A.; Bach, P.; Mailankody, S.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Outcomes of patients with MYC-expressing aggressive B cell non-Hodgkin lymphomas who fail two or more lines of therapy
    Meeting Abstract

    Landsburg, D. J.; Nasta, S.; Svoboda, J.; Mato, A. R.; Schuster, S. J.; Sargent, R. L.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer
    Meeting Abstract

    Kelly, R. J.; Lee, J.; Bang, Y. J.; Almhanna, K.; Murphy, M. A. B.; Catenacci, D. V. T.; Chung, H. C.; Wainberg, Z. A.; Gibson, M.; Lee, K. W.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 1 multicenter study evaluating the safety and efficacy of MHC class II-restricted MAGE-A3/A6 T-cell receptor engineered T cells (KITE-718) in patients with advanced cancers
    Meeting Abstract

    Kebriaei, P.; Klebanoff, C. A.; Creelan, B. C.; Hong, D. S.; Blumenschein, G. R.; Drakaki, A.; Tewari, A.; Thomrongsith, L.; Jiang, Y.; Jain, R. K.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma
    Meeting Abstract

    Kelly, C. M.; Bowler, T. G.; Munhoz, R. R.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Dholakia, R.; Condy, M. M.; Singer, S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save